Cancer Disease-Oriented-Drug Development Examples. The approval of Imatinib in 2001 for the chronic myeloid leukemia highlighted a new therapeutic concept due to its novel mechanism of action and the exceptional tumor response and survival outcome observed in relapsed patients, otherwise condemned to death after resistance to previous chemotherapy schemes.
The before-mentioned made of this drug the first real masterpiece of the new millennium.
In parallel with new technological developments and new drug discovery/delivery to the clinical setting, the apparition of genomics and proteomics is considered to be a seminal advance in oncology, increasing our understanding of cancer biology since the nineties.
From then up to-now, we have increased basic research and clinical opportunities with more targets and molecules than ever, molecules with desirable features as higher specificity, higher selectivity and lower toxicity.
There are also new drug development issues that apply special strategies just from their
inception: increased therapeutic index, more effectiveness in the resistant disease
replacement of previous drugs not always necessary, as well as disease-oriented drugs.
This last type of drugs, with novel activities and/or sites of action, are developed
according to pharmacological issues but also to the biology of a specific tumor model.
Then the use of this strategy is exemplified in five tumor models: non-small cell lung carcinoma,
breast carcinoma, ovarian carcinoma new biology interventions came to breast cancer
treatment several years ago, with the discovery of human epidermal growth factor receptor inhibitors, bone remodeling agents, hormones with different mechanisms of action at the estrogen receptor, new cytostatic that quite changed the natural disease history in a meta static setting
setting, cell cycle inhibitors and poly-ADP ribose polymerase inhibitors among
others. Recently, the introduction of therapeutic vectorized antibodies
antibodies such as immunotherapy with checkpoint inhibitors.
Cancer Stud Mol Med Open J. 2022; 7(1): 1-2. doi: 10.17140/CSMMOJ-7-132